Advertisement

Pharmaceutical Research

, 36:55 | Cite as

Correction to: Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers

  • Issey Takehara
  • Takashi Yoshikado
  • Keiko Ishigame
  • Daiki Mori
  • Ken-ichi Furihata
  • Nobuaki Watanabe
  • Osamu Ando
  • Kazuya Maeda
  • Hiroyuki KusuharaEmail author
  • Yuichi Sugiyama
Correction
  • 585 Downloads

Correction to: Pharm Res (2018) 35: 138

  https://doi.org/10.1007/s11095-018-2416-3

There was a miscalculation of coproporphyrin I AUC0-24h in the published article (Volume 35, Number 7). After the correction of AUC0-24h, AUC ratio and R-square were re-calculated. Then, following corrections were made in the abstract, the body, Fig. 3, Fig. 4 and Table 2 in this article. The interpretation of data in this article was not influenced.

The corrected sentences are below.

Page 1.

Abstract

line 20: coproporphyrin I (r2 = 0.78).

line 23: (r2 = 0.48–0.70).

Page 5.

Effect of Rifampicin on the Plasma Concentrations of Coproporphyrin I.

line 4: 2.3- and 3.5-times higher.

Correlations between the AUC0–24h of Endogenous OATP1B Substrates, and of these with the AUC0–24h of Atorvastatin.

line 6: coproporphyrin I (r2 = 0.78).

line 8: atorvastatin (r2 of 0.65, 0.70 and 0.48, respectively).

The corrected Figures and Table appears below.

Page 9.

Fig. 3e

Page 10.

Table 2, line 6 Coproporphyrin I.

Probe drug

Control

+P

+RIF300

Fold changea

+RIF600

Fold changea

Coproporphyrin I

nd

16.8 ± 1.6

38.1 ± 2.7**

2.3 ± 0.1

57.8 ± 3.8**,††

3.5 ± 0.1

Fig. 4 a Correlation between AUC0-24h of GCDCA-S and CP-I. b Correlation between AUC0-24h of CP-I and atorvastatin

Notes

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Issey Takehara
    • 1
    • 2
  • Takashi Yoshikado
    • 3
    • 4
  • Keiko Ishigame
    • 4
  • Daiki Mori
    • 2
  • Ken-ichi Furihata
    • 5
  • Nobuaki Watanabe
    • 6
  • Osamu Ando
    • 6
  • Kazuya Maeda
    • 2
  • Hiroyuki Kusuhara
    • 4
    Email author
  • Yuichi Sugiyama
    • 2
  1. 1.Biomarker DepartmentDaiichi Sankyo Co. Ltd.TokyoJapan
  2. 2.Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical SciencesThe University of TokyoTokyoJapan
  3. 3.Laboratory of Clinical PharmacologyYokohama University of PharmacyYokohama-shiJapan
  4. 4.Sugiyama Laboratory, RIKEN Innovation CenterRIKENYokohamaJapan
  5. 5.P-One ClinicKeikokai Medical CorpTokyoJapan
  6. 6.Drug Metabolism & Pharmacokinetics Research LaboratoriesDaiichi Sankyo Co., Ltd.TokyoJapan

Personalised recommendations